Dexamethasone

Generic Name
Dexamethasone
Brand Names
Baycadron, Ciprodex, Decadron, Dexamethasone Intensol, Dextenza, Dioptrol, Hexadrol, Hidex 6-day Taper, Maxidex, Maxitrol, Neofordex, Ozurdex, Taperdex 12 Day Taper, Taperdex 6 Day Taper, Taperdex 7-day Taper, Tobradex, Zcort 7 Day Taper
Drug Type
Small Molecule
Chemical Formula
C22H29FO5
CAS Number
50-02-2
Unique Ingredient Identifier
7S5I7G3JQL
Background

Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like hydrocortisone and prednisolone.
...

Indication

Dexamethasone and ciprofloxacin otic suspension is indicated for bacterial infections with inflammation in acute otitis media and acute otitis externa. Intramuscular and intravenous injections are indicated for a number of endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, an...

Associated Conditions
Acute Gouty Arthritis, Acute Leukemia, Acute Otitis Externa, Acute Otitis Media (AOM), Adrenocortical Hyperfunction, Adrenocortical Insufficiency, Allergic Conjunctivitis (AC), Alopecia Areata (AA), Ankylosing Spondylitis (AS), Aspiration Pneumonitis, Asthma, Atopic Dermatitis, Berylliosis, Bullous dermatitis herpetiformis, Bursitis, Chorioretinitis, Choroiditis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Conjunctivitis, Contact Dermatitis, Cushing's Syndrome, Dermatitis, Diabetic Macular Edema (DME), Discoid Lupus Erythematosus (DLE), Drug hypersensitivity reaction, Edema of the cerebrum, Epicondylitis, Episcleritis, Erythroblastopenia, Eye Infections, Eye allergy, Glaucoma, Hypercalcemia, Immune Thrombocytopenia (ITP), Infection, Inflammation, Inflammation of the External Auditory Canal, Intraocular Inflammation, Iridocyclitis, Iritis, Keloids Scars, Keratitis, Lichen Planus (LP), Lichen simplex chronicus, Loeffler's syndrome, Lymphoma, Macular Edema, Meningitis caused by Mycobacterium Tuberculosis, Middle ear inflammation, Mucosal Inflammation of the eye, Multiple Myeloma (MM), Muscle Inflammation caused by Cataract Surgery of the eye, Mycosis Fungoides (MF), Necrobiosis lipoidica diabeticorum, Non-infectious Posterior Uveitis, Ocular Infections, Irritations and Inflammations, Ocular Inflammation, Ocular Inflammation and Pain, Ocular Irritation, Ocular Itching, Ophthalmia, Sympathetic, Optic Neuritis, Otitis Externa, Pemphigus, Perennial Allergic Rhinitis (PAR), Phlyctenular keratoconjunctivitis, Postoperative Infections of the eyes caused by susceptible bacteria, Posttraumatic Osteoarthritis, Regional Enteritis, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Rosacea, Sarcoidosis, Scleritis, Seasonal Allergic Rhinitis, Secondary thrombocytopenia, Serum Sickness, Severe Seborrheic Dermatitis, Stevens-Johnson Syndrome, Synovitis, Systemic Lupus Erythematosus, Tenosynovitis, Trichinosis, Tuberculosis (TB), Ulcerative Colitis, Uveitis, Vernal Keratoconjunctivitis, Acquired immune hemolytic anemia, Acute rheumatic carditis, Anterior eye segment inflammation, Corticosteroid-responsive dermatoses, Ear infection-not otherwise specified caused by susceptible bacteria, Exfoliative erythroderma, Granuloma annulare lesions, Non-suppurative Thyroiditis, Ocular bacterial infections, Severe Psoriasis, Steroid-responsive inflammation of the eye, Swelling of the eyes, Varicella-zoster virus acute retinal necrosis, Watery itchy eyes
Associated Therapies
-
Clinical Trials
Related News

A Study to Investigate Subcutaneous Isatuximab in Combination With Weekly Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma

First Posted Date
2024-04-10
Last Posted Date
2024-11-22
Lead Sponsor
Sanofi
Target Recruit Count
64
Registration Number
NCT06356571

Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)

First Posted Date
2024-04-09
Last Posted Date
2024-12-09
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
220
Registration Number
NCT06353386
Locations
🇨🇦

Centre Hospitalier de l'Université de Montréal ( Site 0200), Montréal, Quebec, Canada

🇵🇱

Uniwersyteckie Centrum Kliniczne ( Site 1405), Gdansk, Pomorskie, Poland

🇬🇧

Addenbrooke's Hospital ( Site 1902), Cambridge, Cambridgeshire, United Kingdom

and more 50 locations

ON 123300 (Narazaciclib) and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma

First Posted Date
2024-04-08
Last Posted Date
2024-10-03
Lead Sponsor
Adriana Rossi
Target Recruit Count
36
Registration Number
NCT06351644
Locations
🇺🇸

Mount Sinai Health System, New York, New York, United States

Minimal Residual Disease-based Strategy With T-Cell Redirector After Treatment With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (D-VRd) in Newly Diagnosed Multiple Myeloma

First Posted Date
2024-04-08
Last Posted Date
2024-04-08
Lead Sponsor
Nantes University Hospital
Target Recruit Count
103
Registration Number
NCT06353022
Locations
🇫🇷

CHU Montpellier, Montpellier, France

🇫🇷

CH Lyon Sud, Lyon, France

🇫🇷

CH de la Côte Basque, Bayonne, France

and more 17 locations

A Clinical Pharmacological Study of Dose Halving of Dexamethasone in Pregnant Women With Preterm Labour With Preterm Birth at Greater Than or Equal to 34 Gestational Weeks (34GW+)

Not Applicable
Not yet recruiting
Conditions
Respiratory Distress Syndrome of Newborn
Interventions
Drug: Dexamethasone
First Posted Date
2024-04-05
Last Posted Date
2024-04-16
Lead Sponsor
Peking University Third Hospital
Target Recruit Count
48
Registration Number
NCT06350565

Dara-RVd Induction for Newly Diagnosed Multiple Myeloma With Autologous Stem Cell Transplantation

First Posted Date
2024-04-04
Last Posted Date
2024-10-11
Lead Sponsor
UNC Lineberger Comprehensive Cancer Center
Target Recruit Count
39
Registration Number
NCT06348147
Locations
🇺🇸

UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States

Talquetamab in Combination With Iberdomide and Dexamethasone for Relapsed or Refractory Multiple Myeloma

First Posted Date
2024-04-04
Last Posted Date
2024-04-04
Lead Sponsor
Thomas Martin, MD
Target Recruit Count
38
Registration Number
NCT06348108
Locations
🇺🇸

University of Calfornia, San Francisco, San Francisco, California, United States

Bortezomib, Pomalidomide, Dexamethasone For Systemic AL Amyloidosis

First Posted Date
2024-04-02
Last Posted Date
2024-05-14
Lead Sponsor
Jin Lu, MD
Target Recruit Count
40
Registration Number
NCT06342466
Locations
🇨🇳

Peking University People's Hospital, Beijing, Beijing, China

Ma-Spore ALL 2020 Study

First Posted Date
2024-03-28
Last Posted Date
2024-03-28
Lead Sponsor
National University Hospital, Singapore
Target Recruit Count
500
Registration Number
NCT06336395
Locations
🇲🇾

University Malaya Medical Centre, Kuala Lumpur, Malaysia

🇲🇾

Subang Jaya Medical Centre, Kuala Lumpur, Malaysia

🇸🇬

KK Women's and Children's Hospital, Singapore, Singapore

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

First Posted Date
2024-03-19
Last Posted Date
2024-12-04
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
171
Registration Number
NCT06317662
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy